MONMOUTH JUNCTION, N.J., May 10, 2012 /PRNewswire/ -- Tris Pharma, a technology driven specialty pharmaceutical company, announced today the joining of Ms. Amanda Wohlleber as Vice President of Scale up and Technical Services effective immediately and the promotion of their key manufacturing executive, Rajul Parikh.
Amanda brings more than 20 years of pharmaceutical manufacturing and tech service experience to Tris’ technology and manufacturing teams. “With our continued growth and expansion of manufacturing, we had been looking for a seasoned technical leader to facilitate a seamless transition from R&D to manufacturing,” said Ketan Mehta, President and CEO of Tris Pharma, and added, “Amanda is a versatile pharmaceutical professional steep in manufacturing and quality areas and fills a crucial gap in our technology offering.” Furthermore, Dr. Mahdi Fawzi, EVP and Chief Scientific Officer noted, “With anticipated launch of our key new NDA products, this is a very strategic and important addition. Tris’ young team has developed unique technology driven new products and Amanda will be a key executive in ensuring successful transition from lab to production floor.”
Amanda has worked on a multitude of dosage forms from metered-dose inhalers, nasal products, solid dosage, oral liquid, topical and suppositories. She started her career in manufacturing at Armstrong Pharmaceuticals in Massachusetts. After spending about 10 years in the Operations environment, she spent the next 10 years at three different generic companies in Validation, Tech Service, and Quality Assurance positions at senior levels. She has a B.S. in Mechanical Engineering with a concentration in Manufacturing from Clarkson University and completed her MBA from Simmons College in Boston, MA. At Tris, Amanda will be in charge of all Scale up and Validation as well as providing Technical assistance to the manufacturing group.
Tris also announced promotion of Rajul Parikh to the position of Vice President, Operations. Rajul has successfully managed and supervised all aspects of Tris’ growth over the last seven years. He will continue managing all their manufacturing, packaging, facilities, and engineering activities.
About Tris Pharma
Tris Pharma is a specialty pharmaceutical company focused on the research and development of technologies driven products. Through its OralXR+ platform, Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris’ Nobuse platform provides abuse-deterrence for opioids and other abuse-prone drugs. Tris’ R&D and manufacturing facilities are located in Monmouth Junction, New Jersey, USA. For more information, please visit www.trispharma.com.
SOURCE Tris Pharma
